item management s discussion and analysis of financial condition and results of operations financial review results of operations sales the following table details the components of sales growth by segment for the last three years components of change total change price volume exchange total net sales vs 
vs 
vs 
total us vs 
vs 
vs 
total international vs 
vs 
vs 
pharmaceutical products segment a vs 
vs 
vs 
diagnostic products segment b vs 
vs 
vs 
hospital products segment a vs 
vs 
vs 
ross products segment b vs 
vs 
vs 
international segment vs 
vs 
vs 
a in  management of the vascular medicine franchise was transferred from the pharmaceutical products segment to the hospital products segment 
percentage changes for and have been restated to reflect this transfer 
b in  management of the fact plus product franchise was transferred from the diagnostic products segment to the ross products segment 
percentage changes for  and reflect this transfer 
sales of new products in are estimated to be million  led by the pharmaceutical  hospital and diagnostic segments 
increases  as disclosed in note  in adult nutritionals in all three years and in anti infectives in were primarily due to unit increases 
the decreases in anti infectives for and were due primarily to unit decreases 
operating earnings gross profit margins sales less cost of products sold  including distribution expenses were percent of net sales in and  and percent in excluding the charges described in note relating to the fda consent decree  the gross profit margin for would have been percent 
gross profit margins in all three years were affected by unfavorable product mix  primarily pharmaceuticals  and the negative effect of the relatively stronger us dollar 
gross profit margins in all years were also affected by productivity improvements  partially offset by higher project expenses for new products  higher manufacturing capacity costs for anticipated unit growth  and the effects of inflation and competitive pricing pressures in some product lines 
in the us  states receive price rebates from manufacturers of infant formula under the federally subsidized special supplemental food program for women  infants  and children 
there are also rebate programs for pharmaceutical products 
these rebate programs continue to have a negative effect on the gross profit margins of the ross and pharmaceutical products segments 
in august  geneva pharmaceuticals  inc began shipments of generic hytrin in the united states  which has adversely impacted abbott s hytrin sales 
sales of hytrin in the united states amounted to million  million  and million in   and  respectively 
as a result of the consent decree entered into with the us government in  as discussed in note  abbott is prohibited from manufacturing or distributing certain diagnostic products until abbott ensures the processes in its lake county  ill  diagnostics manufacturing operations conform with the us food and drug administration s fda quality system regulation qsr 
the consent decree resulted in a charge of million in the third quarter of abbott estimates that sales were negatively impacted by approximately million  and earnings per share were negatively impacted by approximately cents per share 
under the terms of the amended consent decree  abbott must ensure its diagnostics manufacturing operations are in conformance with the qsr by various dates through january  the fda will determine abbott s conformance with the qsr after an inspection of abbott s facilities 
if the fda concludes that the operations are not in conformance with the qsr as of the date required  abbott may be subject to additional costs 
research and development expense was billion in and represented percent of net sales in  compared to percent of net sales in  and percent of net sales in the increase in research and development expenses in was concentrated primarily in the pharmaceutical  diagnostic and hospital segments 
research and development expenditures continue to be concentrated on pharmaceutical and diagnostic products 
selling  general and administrative expenses increased percent in  net of the favorable effect of the relatively stronger us dollar of percent  compared to increases of percent in  and percent in the net increases  exclusive of exchange impact  reflect inflation and additional selling and marketing support primarily in the international  pharmaceutical and hospital segments 
in addition  and reflect litigation charges  and includes merger costs of approximately million 
abbott s income from tap pharmaceutical products inc tap joint venture in was adversely affected as a result of an increase in a litigation reserve related to the us department of justice investigation of tap s marketing and sales practices for lupron 
while it is not feasible to predict the outcome of these proceedings with certainty  management is of the opinion that their ultimate disposition should not have a material adverse effect on abbott s financial position or ongoing cash flow and results of operations  but that they could have a material adverse effect on abbott s cash flow and results of operations for a particular period 
interest income expense  net net interest expense decreased in and due to a lower level of borrowings and a higher level of investment securities 
net interest expense increased in due primarily to a higher level of borrowings as a result of business acquisitions 
taxes on earnings the effective income tax rates were percent in and percent in and the tax rate for was reduced  in part  by the domestic dividend exclusion applicable to the increased earnings of tap pharmaceutical products inc in addition  the tax rates for and were unfavorably impacted by the reduction in tax incentive grants for puerto rico operations 
financial condition cash flow abbott expects annual cash flow from operating activities to continue to approximate or exceed abbott s capital expenditures and cash dividends 
debt and capital at december   abbott s bond ratings were aaa by standard poor s corporation and aa by moody s investors service 
abbott has readily available financial resources  including unused domestic lines of credit of billion  which support domestic commercial paper borrowing arrangements 
as a result of the proposed acquisition of basf s pharmaceutical business  abbott s credit ratings are under review  and it is expected that the ratings may be adjusted to reflect the increased borrowings that will finance the acquisition 
in addition  available lines of credit  which will support increased commercial paper borrowings  increased to billion in february under a registration statement filed with the securities and exchange commission sec in february  abbott may issue up to billion of securities in the future 
of the billion  abbott may issue million either in the form of debt securities or common shares without par value 
the remaining billion may be issued in the form of debt securities 
previously  under a registration statement filed with the sec in  abbott may have issued million of securities  which is now included in the billion 
during the last three years  abbott purchased  of its common shares at a cost of billion  including million shares of the million shares authorized for purchase by abbott s board of directors in june working capital at december    and  working capital was billion  billion  and million  respectively 
capital expenditures capital expenditures of billion in  million in  and million in were principally for upgrading and expanding manufacturing  research and development  and administrative support facilities in all segments and for laboratory instruments and hospital equipment placed with customers 
this level of capital expenditures is expected to continue  with an increased proportion dedicated to the hospital  international and diagnostic segments 
legislative issues abbott s primary markets are highly competitive and subject to substantial government regulation 
abbott expects debate to continue at both the federal and state levels over the availability  method of delivery  and payment for health care products and services 
if legislation is enacted  it could have the effect of reducing prices  or reducing the rate of price increases for medical products and services 
international operations are also subject to a significant degree of government regulation 
it is not possible to predict the extent to which abbott or the health care industry in general might be adversely affected by these factors in the future 
a more complete discussion of these factors is contained in item  business 
business combinations and divestiture on december   abbott and basf ag reached an agreement through which abbott will purchase the pharmaceutical business of basf  subject to approval of government regulators 
the purchase price is billion 
abbott estimates that the acquisition  if completed  will result in purchase accounting charges of approximately billion for in process research and development in  and will result in goodwill and intangibles of approximately billion 
the purchase will be financed by us dollar and euro based borrowings described under debt and capital 
on november   abbott completed a merger transaction with perclose  inc  which was accounted for as a pooling of interests transaction 
abbott issued approximately million common shares to perclose shareholders  and perclose s outstanding stock options were converted into options to purchase approximately million abbott common shares 
merger related charges of approximately million are included in selling  general and administrative expenses for abbott s consolidated financial statements for prior periods have been restated to include perclose and are not significantly different than previously reported amounts 
in  abbott acquired certain assets of glaxo wellcome inc s us anesthesia business for approximately million in cash 
a substantial portion of the purchase price was allocated to intangible assets  which are amortized on a straight line basis over years 
in  abbott acquired the common stock of international murex technologies corporation  a manufacturer of medical diagnostic products  for approximately million in cash 
a substantial portion of the purchase price was allocated to goodwill  which is amortized on a straight line basis over years 
had these acquisitions taken place on january of the previous years  consolidated sales and income would not have been significantly different from reported amounts 
in january  abbott sold its agricultural products business to sumitomo chemical co  ltd  resulting in a million gain 
under the transaction  sumitomo acquired research and development  sales  marketing  and support operations for abbott s entire line of naturally occurring biopesticides  plant growth regulators and other products for agriculture  public health and forestry 
bulk active ingredient manufacturing rights were retained by abbott 
for the full year  abbott recorded approximately million in sales from this business 
recently issued accounting standards in june  the financial accounting standards board issued statement of financial accounting standards no 
 accounting for derivative instruments and hedging activities 
this statement requires the recognition of the fair value of derivatives as either assets or liabilities 
adoption of the provisions of this statement on january   will result in a transition credit to income of approximately million in the emerging issues task force eitf issued eitf issues no 
 accounting for shipping and handling fees and costs  and no 
 accounting for certain sales incentives  which address the classification of shipping and handling fees and costs and various sales incentives  and were effective for the fourth quarter of the adoption of the provisions of these eitf issues did not have a material effect on abbott s financial statements 
the securities and exchange commission sec has issued staff accounting bulletin sab no 
 revenue recognition in financial statements  as amended on june  sab no 
provides the sec staff s views in applying generally accepted accounting principles to selected revenue recognition issues  and was effective beginning in the fourth quarter of adoption of the provisions of this sab did not have a material effect on abbott s financial statements 
euro conversion on january   the european economic and monetary union took effect and introduced the euro as the official single currency of the participating member countries 
on that date  the currency exchange rates of the participating countries were fixed against the euro 
there is a three year transition to the euro  and at the end of  the legacy currencies will be eliminated 
costs required to prepare for the euro are not material to abbott s financial position  results of operations or cash flows 
the impact  if any  of the euro on abbott s competitive position is unknown 
private securities litigation reform act of a caution concerning forward looking statements under the safe harbor provisions of the private securities litigation reform act of  abbott cautions investors that any forward looking statements or projections made by abbott  including those made in this item  are subject to risks and uncertainties that may cause actual results to differ materially from those projected 
economic  competitive  governmental  technological and other factors that may affect abbott s operations are discussed in exhibit item a 
quantitative and qualitative disclosures about market risk financial instruments and risk management unaudited interest rate sensitive financial instruments abbott does not currently use derivative financial instruments  such as interest rate swaps  to manage its exposure to changes in interest rates for its debt instruments and investment securities 
as of december   and  abbott had million and million  respectively  of domestic commercial paper outstanding with an average interest rate of and  respectively  and with an average remaining life of three days and days  respectively 
the fair market value of long term debt at december   and  amounted to billion  and consisted primarily of fixed rate average of debt with maturities through as of december   and  the fair market value of current and long term investment securities maturing through amounted to million and million  respectively 
approximately percent and percent of these investments as of december   and  respectively  have fixed interest rates average of  while the remaining investments have variable rates 
a hypothetical basis point change in the interest rates would not have a material effect on cash flows  income or market values 
a basis point change is a reasonably possible near term change in rates 
market price sensitive financial instruments abbott maintains a portfolio of available for sale equity securities from strategic technology acquisitions 
the market value of these investments was approximately million and million  respectively  as of december   and a hypothetical percent decrease in the share prices of these investments would decrease the fair value by approximately million 
a percent decrease is a reasonably possible near term change in share prices 
foreign currency sensitive financial instruments purchased us dollar call options abbott s foreign subsidiaries purchase us dollar call options as a hedge of anticipated intercompany purchases by these foreign subsidiaries whose functional currency  primarily european currencies and japanese yen  is not the us dollar 
at december   there were no such contracts outstanding and at december   abbott held million of these contracts 
foreign currency forward exchange contracts abbott enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated intercompany loans and trade payables and third party trade payables and receivables 
the contracts are marked to market  and resulting gains or losses are reflected in income and are generally offset by losses or gains on the foreign currency exposure being hedged 
at december   and  abbott held billion and billion  respectively  of such contracts which all mature in the next calendar year 
the following table reflects the contracts outstanding at december   and contract amount average exchange rate fair and carrying value contract amount average exchange rate fair and carrying value dollars in millions receive primarily us dollars in exchange for the following currencies euro british pound japanese yen dutch guilder spanish peseta canadian dollar australian dollar taiwan dollar all other currencies n a n a total   
